Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2012
02/09/2012US20120034300 Stabilized zolpidem pharmaceutical compositions
02/09/2012US20120034297 Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
02/09/2012US20120034296 Prolonged duration local anesthesia with minimal toxicity
02/09/2012US20120034293 Transdermal delivery of cannabinoids
02/09/2012US20120034292 Composition For Transdermal Delivery Of Fentanyl
02/09/2012US20120034291 Nanoimprinting of silk fibroin structures for biomedical and biophotonic applications
02/09/2012US20120034279 Transscleral delivery
02/09/2012US20120034278 Ophthalmic preparation containing menthyl ester of indomethacin
02/09/2012US20120034276 Solid preparation
02/09/2012US20120034275 Powder formulations for inhalation, comprising enantiomerically pure beta agonists
02/09/2012US20120034274 Pharmaceutical composition comprising one or more fumaric acid esters
02/09/2012US20120034272 Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin II antagonist and/or a diuretic
02/09/2012US20120034271 Injectable in-situ crosslinked hydrogel and methods of making and using thereof
02/09/2012US20120034270 S1P Receptors Modulators
02/09/2012US20120034266 Methods and compositions for improving immune response by a nutraceutical antioxidant
02/09/2012US20120034251 Pharmaceutical composition for treating or preventing cancer by inducing dendritic cell-like differentiation from monocytes to improve anticancer immune activity
02/09/2012US20120034250 Condensed pyrrolopyridine derivative
02/09/2012US20120034243 Method of Administering an Antibody
02/09/2012US20120034240 Perlecan as a biomarker for renal dysfunction
02/09/2012US20120034236 Co-targeting of aurora a kinase and lim kinase 1 for cancer therapy
02/09/2012US20120034233 Methods of Treating an Overweight or Obese Subject
02/09/2012US20120034229 Monoclonal antibodies directed against lg4-5 domain of alpha3 chain of human laminin-5
02/09/2012US20120034219 Uses of il-23 agonists and antagonists; related reagents
02/09/2012US20120034218 RBM3 in Colorectal Cancer Prognostics
02/09/2012US20120034217 Anti-neoplastic compositions comprising extracts of black cohosh
02/09/2012US20120034216 Spiroketals
02/09/2012US20120034214 Methods and kits for determining the prognosis of pulmonary sarcoidosis
02/09/2012US20120034213 TREATMENT WITH ANTI-ErbB2 ANTIBODIES
02/09/2012US20120034211 EGFR antibodies comprising modular recognition domains
02/09/2012US20120034205 Pkc activators and anticoagulant in regimen for treating stroke
02/09/2012US20120034193 Treatment of neurotrophic factor mediated disorders
02/09/2012US20120034189 Means and methods for durable inhibition of pathogens
02/09/2012US20120034187 Hepatitis C Inhibitor Compounds
02/09/2012US20120034186 Indoline scaffold shp-2 inhibitors and method of treating cancer
02/09/2012US20120034184 4'-substituted nucleoside derivatives as inhibitors of hcv rna replication
02/09/2012US20120034176 Sulphurated derivatives of resorcinol, preparation of same and cosmetic uses thereof
02/09/2012US20120034172 Pharmaceutical formulation comprising a phosphodiesterase inhibitor
02/09/2012US20120034171 Abuse-proofed dosage form
02/09/2012US20120034169 Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
02/09/2012US20120034167 Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer
02/09/2012US20120034159 Antibodies that bind both bcma and taci
02/09/2012US20120031785 Compositions and methods for increasing lean muscle mass and/or reducing fat gain
02/09/2012US20120031403 Dry powder formulation comprising a phosphodiesterase inhibitor
02/09/2012DE102010038842A1 New aptamer that specifically binds to human tau protein or its fragment, useful e.g. in vitro for isolating, purifying and/or detecting tau protein, and to treat cerebral infarction, pick disease and/or progressive supranuclear palsy
02/09/2012DE102010033527A1 Quetiapin-Tabletten Quetiapine tablets
02/09/2012CA2847661A1 Compositions comprising oleuropeins and flavanoids and their use
02/09/2012CA2817879A1 Apparatus and process for encapsulating capsules or other solid dosage forms within capsules
02/09/2012CA2810267A1 Combination of compounds for treating or preventing skin diseases
02/09/2012CA2810150A1 P2x4 receptor antagonist
02/09/2012CA2807589A1 Combinations of hepatitis c virus inhibitors
02/09/2012CA2807528A1 St-246 liquid formulations and methods
02/09/2012CA2807510A1 Disorders of neuronal connectivity
02/09/2012CA2807507A1 Treatment of mitochondrial diseases with naphthoquinones
02/09/2012CA2807498A1 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
02/09/2012CA2807483A1 Devices, systems, and methods for excavating cancer cells
02/09/2012CA2807459A1 Process for preparing a compound by a novel sandmeyer-like reaction using a nitroxide radical compound as a reaction catalyst
02/09/2012CA2807406A1 Pharmaceutical formulation comprising a phosphodiesterase inhibitor
02/09/2012CA2807376A1 Collagen-based implants for sustained delivery of drugs
02/09/2012CA2807357A1 Microparticle formulation for pulmonary drug delivery of anti-infective molecule for treatment of infectious diseases
02/09/2012CA2807305A1 Hepatitis c virus inhibitors
02/09/2012CA2807292A1 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat proteins
02/09/2012CA2807283A1 Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease
02/09/2012CA2807274A1 Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof
02/09/2012CA2807266A1 Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair
02/09/2012CA2807263A1 Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties
02/09/2012CA2807256A1 Dry powder formulation comprising a phosphodiesterase inhibitor
02/09/2012CA2807230A1 Compounds and compositions for mitigating tissue damage and lethality
02/09/2012CA2807224A1 Preparation for treatment of spinal cord injury
02/09/2012CA2807191A1 Glycolipid for treatment of ischemia reperfusion injury
02/09/2012CA2807187A1 Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
02/09/2012CA2807174A1 Use of inhibitors of porphobilinogen deaminase in the treatment of congenital erythropoietic porphyria
02/09/2012CA2807150A1 Corticosteroids for the treatment of joint pain
02/09/2012CA2807149A1 Novel treatment of prostate carcinoma
02/09/2012CA2807139A1 Liposome targeting compounds and related uses
02/09/2012CA2807135A1 Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
02/09/2012CA2807093A1 Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
02/09/2012CA2807078A1 Acid addition salts of the 2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-(methyl)amino]ethoxy]-n-methyl-n-[3-(4-methylpiperazin-1-yl)cyclohexyl] acetamide and the use thereof asbradykinin b1 receptor antagonists
02/09/2012CA2807075A1 Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine
02/09/2012CA2807069A1 Use of sigma ligands in opioid-induced hyperalgesia
02/09/2012CA2807033A1 Composition for regeneratng normal tissue from fibrotic tissue
02/09/2012CA2806956A1 Methods and pharmaceutical compositions for treating adverse or deleterious sequellae of traumatic brain injury
02/09/2012CA2806829A1 Bone-targeting bisphosphonate duplex drugs
02/09/2012CA2806825A1 Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
02/09/2012CA2806752A1 Oral dosage form of pregabalin
02/09/2012CA2806664A1 Arylsulfonamide derivatives, compositions, and methods of use
02/09/2012CA2806660A1 Compositions and methods for enhancing the effectiveness of systemic, hipec, ip, and related cancer treatments
02/09/2012CA2806657A1 Highly crystalline valsartan
02/09/2012CA2806636A1 Use of glyceryl trinitrate for treating traumatic edema
02/09/2012CA2806519A1 Beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and process for obtaining them
02/09/2012CA2806427A1 Compositions for proliferation of cells and related methods
02/09/2012CA2806190A1 N-acylsulfonamide apoptosis promoters
02/09/2012CA2806185A1 Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent
02/09/2012CA2806015A1 N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein
02/09/2012CA2805827A1 Chemical compounds
02/09/2012CA2805525A1 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
02/09/2012CA2805523A1 Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
02/09/2012CA2805440A1 Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
02/09/2012CA2805358A1 Compounds with antibacterial activity against clostridium
02/09/2012CA2805265A1 Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
02/09/2012CA2805206A1 Benzenesulfonamide-compound treatment of a pathological condition linked to an excessive effect of tnf
1 ... 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 ... 7860